-
Signature
-
/s/ John Sellers, Attorney-in-fact
-
Stock symbol
-
NPTN
-
Transactions as of
-
Aug 3, 2022
-
Transactions value $
-
$0
-
Form type
-
4
-
Date filed
-
8/5/2022, 06:48 PM
Transactions Table
Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
transaction |
NPTN |
Common Stock |
Disposed to Issuer |
|
-34.4K |
-100% |
|
0 |
Aug 3, 2022 |
Direct |
F1 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
transaction |
NPTN |
Non-Qualified Stock Option (right to buy) |
Disposed to Issuer |
|
-14.1K |
-100% |
|
0 |
Aug 3, 2022 |
Common Stock |
14.1K |
$4.33 |
Direct |
F2 |
transaction |
NPTN |
Non-Qualified Stock Option (right to buy) |
Disposed to Issuer |
|
-12.5K |
-100% |
|
0 |
Aug 3, 2022 |
Common Stock |
12.5K |
$6.78 |
Direct |
F2 |
transaction |
NPTN |
Non-Qualified Stock Option (right to buy) |
Disposed to Issuer |
|
-8.96K |
-100% |
|
0 |
Aug 3, 2022 |
Common Stock |
8.96K |
$8.56 |
Direct |
F2 |
transaction |
NPTN |
Non-Qualified Stock Option (right to buy) |
Disposed to Issuer |
|
-7.52K |
-100% |
|
0 |
Aug 3, 2022 |
Common Stock |
7.52K |
$9.20 |
Direct |
F2 |
transaction |
NPTN |
Non-Qualified Stock Option (right to buy) |
Disposed to Issuer |
|
-2.66K |
-100% |
|
0 |
Aug 3, 2022 |
Common Stock |
2.66K |
$9.41 |
Direct |
F2 |
transaction |
NPTN |
Non-Qualified Stock Option (right to buy) |
Disposed to Issuer |
|
-7.64K |
-100% |
|
0 |
Aug 3, 2022 |
Common Stock |
7.64K |
$10.17 |
Direct |
F2 |
transaction |
NPTN |
Restricted Stock Unit (right to acquire) |
Disposed to Issuer |
|
-5.79K |
-100% |
|
0 |
Aug 3, 2022 |
Common Stock |
5.79K |
$0.00 |
Direct |
F3 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Ihab Saad Tarazi is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.
Explanation of Responses:
Remarks:
Exhibit List Exhibit 24: Authorization Letter